IPP Bureau
BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies
By IPP Bureau - March 14, 2026
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
By IPP Bureau - March 14, 2026
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
By IPP Bureau - March 14, 2026
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
By IPP Bureau - March 14, 2026
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Almirall opens Shanghai hub to power dermatology innovation and China partnerships
By IPP Bureau - March 14, 2026
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
By IPP Bureau - March 13, 2026
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis
By IPP Bureau - March 12, 2026
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues
By IPP Bureau - March 12, 2026
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
By IPP Bureau - March 12, 2026
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
BPL Medical Tech acquires South Korea’s Yozma BMtech
By IPP Bureau - March 12, 2026
Launches advanced bone density systems in India & Dubai
India tackles rare diseases head-on at landmark summit in New Delhi
By IPP Bureau - March 12, 2026
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
By IPP Bureau - March 12, 2026
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure
By IPP Bureau - March 12, 2026
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
By IPP Bureau - March 12, 2026
The FDA classified LifeVac as a Class II medical device
Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
By IPP Bureau - March 12, 2026
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
